- Our Support
- Clinical Trials
- Unfunded Medicines
- RDNZ Education
Meet some of our Team
Dr. Daniel Thurley - General Manager
MBBChir MRCP FFPM
I have been fortunate and humbled over my eleven years at Roche to have experienced first-hand the commitment of my 90,000 colleagues around the World to bring life-changing medicines to patients. Courage, passion and integrity are at the centre of everybody I have worked with.
There is a strong culture in Roche to support every individual to be the best that they can. There is focus both on what we deliver as an individual and how we do this. Managers within the organisation take a keen interest to support the development of everyone to be a leader in their role and to build their knowledge, skills and competencies for success.
The Medicines we discover, research, develop and commercialise to change patients' lives are incredible: we set the bar for success very high to either be first in class and best in disease. The New Zealand team are incredibly dedicated, professional and it is a privilege to lead this group to fulfil our shared ambition: "Doing now what patients need next"
Jan Campbell – Director Medical Affairs
Roche is a great place to work. I should know, I have been here for 17 years now. I've been lucky to work with so many fantastic workmates in the Roche NZ team, which is small enough to feel like my work 'family'. In addition, I work with many colleagues and friends around the globe who make up the Roche network.
So many changes have occurred since I joined the company in 1999 and my role has been no exception. I joined as the first clinical research associate for Roche NZ. This saw me travelling the length and breadth of the country monitoring the development trials undertaken by specialists in clinical research in NZ. It was a brilliant job; combining the satisfaction of seeing the response patients experienced on some of our new medicines, with working with fantastic clinical teams in our hospitals and specialist research centres.
The role quickly expanded as did the medical function within Roche. Today, as Director of Medical Affairs, I lead a team of medical managers, clinical research specialists, quality management, and the pharmacovigilance team. Medical Information also sits in Medical Affairs.
I've experienced cancer treatment myself and know that the most important role we can play is to support the safe use of our medicines so that patients get the best outcomes possible. That just about sums up what motivates me to come to work at Roche.
Kerstie Twiname – Senior Product Strategist
I have been with Roche NZ for ten years.
Over that time I have looked after a number of medicines, including Xenical, NeoRecormon, Tamiflu and now MabThera and Actemra for the treatment of rheumatoid arthritis.
I am responsible for the marketing and sales of these two medicines. I work as closely as I can with the rheumatologists and their teams around the country. I do this to try and help them and their rheumatoid arthritis patients as much as I can. I also want to better understand the issues and to develop the most important and relevant information for them and their patients.
What makes my job worthwhile is hearing the patient case studies where one of our medicines has really made a significant difference to a patient's quality of life.
Nadia Kaienua – Regulatory Affairs Product Manager
I have worked at Roche for around seven years, starting off in Regulatory Compliance and moving through to my current role as a Regulatory Affairs Product Manager. In my role I work as part of the Regulatory Affairs team for Australia and New Zealand.
In New Zealand, every medicine sold must first be registered with the Ministry of Health (Medsafe), and it is my job to ensure this is the case. I review the medicine dossier against NZ legislation and guidelines and determine a strategy to bridge any gaps. I adapt sections of the dossier to fit local requirements before finally submitting the registration application to Medsafe for review.
Medsafe evaluates aspects such as the manufacturing and testing of the medicine (quality) as well as the benefit-risk profile (efficacy and safety) of the medicine as observed in clinical trials (and also in the post-market setting for registered medicines). Once registered, the medicine can then be made available to New Zealand patients.
Any further changes to the quality, safety or efficacy aspects of the medicine once it is registered may also need to be reviewed and approved by Medsafe. I assess whether or not these changes need to be registered; obtaining additional documentation and determining what impact the change may have; before submitting the application to Medsafe to ensure Roche can continue to supply the medicine.
I am also involved in submissions and obtaining approvals for Roche to be able to run clinical trials; giving New Zealand patients an opportunity to receive a medicine which may otherwise not be available to them.
Paul Schon – Senior Product Strategist
I am a Senior Product Strategist leading the Roche cancer products MabThera used in the diseases of non-Hodgkin’s lymphoma (NHL) and GAZYVA used in Chronic Lymphocytic Leukaemia (CLL).
My role is to ensure the seamless introduction of these products into the New Zealand health system.
These products are important to the health of New Zealanders who have cancer. To ensure health care providers are in the best position to access and use these products optimally, I undertake a number of activities to achieve this outcome.
For example in conjunction with the Medical Manager I look to provide ongoing information on our medications. This information is constantly changing as the drug is used more widely and more experience is gained around the world. The sort of information I provide can include updates in the latest medical trial results, including new combinations that have been successful, side effects of the drugs and how to better manage these.
It is important to me as a Kiwi that our citizens get the best products, access, support and information possible to achieve the best outcomes for their disease. Working at Roche I look to achieve that every day.
Tina Stanimiroff – Senior Medical Affairs Assistant
I’ve worked in the Roche NZ affiliate for more than seven years and am a Senior Medical Affairs assistant. My role consists of drug safety oversight and clinical trial administration.
One of my main responsibilities is to ensure that the collection, reporting and handling of safety information associated with Roche products is performed according to global and local regulatory requirements. Reporting all adverse events associated with Roche products within specified timelines is crucial in maintaining the safety profile of our medicines. This ensures that clinicians have the most up-to-date safety information available to them when prescribing medicines for New Zealanders.
I also provide support to the local study team by managing the payments to clinical trial sites and preparing legal documents for clinical trials. The timely preparation of legal documents for clinical trials means that our trials can start as soon as possible, giving New Zealand patients access to innovative medicines sooner rather than later.
Edwina Mandisodza – Quality and SHE Manager
I have been with Roche for five years.
My role is to provide quality and safety, health, and environment (Quality and SHE) oversight for the organisation. This involves quality assurance check and approval of medicines for supply to New Zealand patients. I am responsible for the quality management system to ensure uninterrupted supply of safe medicines to patients and ensure that if anything goes wrong, issues are handled expeditiously to avoid harm to patients.
I help to manage product complaints and coordinate recall / issue management, as well as routine Quality Risk Management. In checking medicines for supply to patients, I am checking that each batch meets NZ registered specifications that include checking each produced batch has the required amount of active pharmaceutical ingredients and meets its attributes for sterility, purity, and strength. This means New Zealanders are assured of high quality, safe, efficacious medicines. All this is done while ensuring sustainability so the impact of our operations on the environment is minimised, and the health and safety of our staff, contractors, and visitors is well taken care of.
Ed Thorpe – Product Strategist
I joined Roche NZ eight months ago, and have been hugely impressed by the team here in Newmarket. Having worked in Europe and Australasia, I can hand on heart say that to date, I have not worked with a group of more committed, professional and fun people, who are really dedicated to patients and passionate about what they do.
I am responsible for our HER2 portfolio, which is our breast cancer franchise. This is the most common cancer in women in NZ, and affects 1/9 women at some point in their lives. The HER2 franchise includes Herceptin which has helped countless women in NZ over the last decade, and two new innovative treatments for breast cancer.
I am responsible for the marketing of the franchise, as well as meeting with clinicians around the country and providing support for educational conferences and meetings to advance healthcare in NZ. These meetings also provide the opportunity to bring in world renowned key opinion leaders to talk with NZ based peers, and share knowledge.
I also work on our patient access programmes, which are designed to help reduce the cost of medicines which are not funded by the Government’s drug-buying agency, PHARMAC. This makes these cutting edge medicines more widely available to the New Zealand public and also allows doctors in New Zealand to have access to the most innovative medicines, often seen as standard of care in the rest of the developed world.